DENOSUMAB ASSOCIATED WITH BONE DENSITY INCREASE AND CLINICAL IMPROVEMENT IN A LONG-TERM HEMODIALYSIS PATIENT. CASE REPORT AND REVIEW OF THE LITERATURE

Abstract

Denosumab is a human monoclonal antibody representing a novel therapy of osteoporosis. Contrary to always other antiosteoporotic drugs, it is not contraindicated in advanced chronic kidney disease, as its pharmacokinetic does not differ from patients with normal kidney function. However, published case reports in chronic kidney disease (CKD) patients stopped the therapy after single dose because of hypocalcemia. We present a case of successful treatment of osteoporosis in a young hemodialysis patient with repeated denosumab doses.

Keywords

• Denosumab
• Bone density
• Hemodialysis
• Hypocalcemia
• Parathormone